

CURRICULUM VITAE – Prof. SONI SAVAI PULLAMSETTI

CONTACT INFORMATION

First Name	Soni
Last Name	Savai Pullamsetti
Degrees/Credentials	Prof. Dr. biol. Hom.,
Institution/Organization	Max-Planck-Institute for Heart and Lung Research Justus Liebig University Giessen
City	Bad Nauheim/Giessen
Sate	Hessen
Country	Germany
Email address	soni.pullamsetti@mpi-bn.mpg.de soni.savai@innere.med.uni-giessen.de
URL for website	http://spullamsettilab.com/ https://www.mpi-hlr.de/pullamsetti-lab
<u>AHA member ID</u>	<u>000220861886</u>

EDUCATION/ WORK RELATED ACHIEVEMENTS

2020 – present	Professor (W3) and chair for Lung Vascular Epigenetics, Cardio Pulmonary Institute, Justus Liebig University Giessen, Germany
2011 – 2020	Research group leader , Molecular Mechanisms of Pulmonary Vascular Diseases, Max Planck Institute for Heart and Lung Research, Bad Nauheim
2017	APL Professor , Justus Liebig University Giessen, Germany
2010 – 2011	Maternity Leave
2008 – 2010	Staff scientist , Department of Lung Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
2006 – 2008	Postdoctoral fellow , Medizinische Klinik und Poliklinik IV/V, Justus Liebig University Giessen, Germany
2002 – 2006	Promotion studies for Dr. biol. hom. , Medizinische Klinik und Poliklinik II, Justus Leibig University Giessen, Germany „ <i>Summa cum laude</i> “
1997 – 1999	Master of Science (MSc) , Department of Biotechnology, Central University, Chattisgarh, India (Gold Medal Award of Distinction)
1994 – 1997	Bachelor of Science (BSc) , Department of Microbiology, Osmania University, Hyderabad, India (Gold Medal Award of Distinction)

LEADERSHIP ROLES/ORGANIZATIONAL ACHIEVEMENTS

2023	Elected member of the LEOPOLDINA, German Academy of Natural Sciences and Medicine
2023	DZL Scientific coordinator of the disease area PH
2023	Steering Board member, Cardio-Pulmonary Institute (CPI)
2022	DZL coordinator for Gene and Cell Therapy initiative across German Centers for Health Research (DZG)
2022	Task force member of 7th world symposium on pulmonary hypertension
2022	Leader for the national epigenomic studies of COVID samples collected by German National Pandemic Cohort Network (NAPKON)
2022	Member of Pulmonary Perspective , Pulmonary hypertension at American Journal of Critical Care and Pulmoanry Medicine (AJRCCM)
2018 – 2021	3CPR Early Career Committee Member of American Heart Association (AHA)
2021– present	Adjunct Faculty “Institute for Lung Health (ILH)”, Justus Liebig University Giessen, Germany

2021– present	Working Group committee member for European Respiratory Society (ERS) Fellowships and Awards
2021– 2027	Academy Committee member , Cardio-Pulmonary Institute (CPI), excellence cluster funded by the German Research Foundation (DFG)
2018	Scientific Organizing Committee of 13th PVRI Annual World Congress on PVD, Barcelona 2019

AWARDS AND HONORS

2023	Elected Fellow of the American Heart Association (FAHA)
2020	Awarded European Research Council (ERC) Consolidator Grant
2017	Romain Pauwels Research Award for outstanding contribution to research in respiratory medicine at European Respiratory Society (ERS), London UK
2015	Dr. Herbert-Stolzenberg-Preis for Excellence in Research award, Justus Liebig University Giessen, Germany
2015	Research Excellence Award at the 56th Annual Congress of the German Respiratory Society (DGP), Berlin, Germany
2013	Young Investigator Award at 5th World Symposium on Pulmonary Hypertension (WSPH), Nice, France
2012	Awarded Excellent Investigator Award at the International Conference On Global Meet Of Biologists, India-2012
2008	Young Scientist Award , Encysive Pharmaceuticals -sponsored programm EtRA
2007	International Trainee Travel Award , American Thoracic Society (ATS), San Francisco, California, USA
2007	Travel Award , Scientific Lung Day Graz, Austria
2007	FEBS Award for joining Advanced Practical and Lecture Course “Viral Expression Vectors for Research and Biotechnology,” University of Tartu, Tartu, Estonia
2005	Rene-Baumgart Foundation Research Award for excellent scientific work for pulmonary hypertension
1997	Gold medalist in Master of Science (MSc) in biotechnology, for scoring highest grades
1997	Gold medalist in Bachelor of Science (BSc) in microbiology, for scoring highest grades
1991-1999	National merit scholarship for the excellence in college studies

SELECTED CONFERENCE SPEAKER INVITATIONS

2022	Vascular Science Seminar Talk at Imperial College London
2021	Plenary lecture at Penn Lung Biology Institute Symposium
2021	Plenary lecture at New York Academy of Sciences
2021	Dalhousie University Seminar Series
2021	VMI/HVI Conference Series
2016, 2022	Invited speaker at the HFA Winter Meeting on Translational Heart Failure Research, Switzerland
2014 – 2022	Invited speaker and moderator of sessions at the American Thoracic Society (ATS)
2016 – 2022	Invited speaker and scientific program organizer at the Pulmonary Vascular Research Institute (PVRI) Annual meetings
2016 – 2022	Invited speaker and moderator of sessions at the American Heart Association (AHA)
2014 – 2021	Invited speaker and moderator of sessions at the European Respiratory Society (ERS) annual meetings
2013 – 2021	Invited speaker at the German Respiratory Society annual meetings
2019	Invited speaker at the Thomas L. Petty Aspen Lung Conference, 62nd Annual Meeting

2018	Invited speaker at the 6 th World symposium on Pulmonary Hypertension (WSPH), Nice, France
2018	Invited speaker at the joint symposium Max Planck-GIBH Center for Regenerative Biomedicine, Hong Kong
2015	Invited speaker at the Grover Conference on Pulmonary Circulation in the “Omics” Era, CO, USA
2016	Invited speaker at the Sir John Vane Symposium, London, UK

EDITORIAL BOARD/ REVIEWING PANEL

- Reviewer of German Research Council (DFG) and European Research Council (ERC) grants
 - Reviewer in a Medicine and Health evaluation panel at the Swedish Research Council
 - European Science Foundation (ESF) College of Expert
 - European Research Society (ERS) Science Council and Executive Committee
 - Expert panel and Rapporteur Research Foundation Flanders (FWO, Med6RP)
 - Expert panel and Rapporteur for grants submitted to Management of University and Research Grants in Spain (AGAUR)
 - Reviewer of Canada Research Chairs Program
 - Reviewer of SSC Grants Pre-Award (RCUK SSC Ltd, Grants)
 - Reviewer of Swiss National Foundation and German Research Foundation
 - Editorial board member of Scientific Reports, Pulmonary Circulation, American Journal of Physiology-Lung Cellular and Molecular Physiology
 - Reviewer at **Science**, **Science Translational Medicine**, Science Advances, Nature Communications, Journal of Clinical Investigation, American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal, Circulation, Circulation Research, Molecular Biology of the Cell, Plos One, American Journal of Physiology - Lung Cellular and Molecular Physiology, FEBS Journal, British Journal of Pharmacology, Respiratory Research, Cellular Physiology and Biochemistry, International Journal of Cardiology
-

ELECTION INTO PROFESSIONAL SOCIETIES

Since 2018	Area leader of the “Excellence Cluster for Cardio Pulmonary Institute (CPI)”
2018	Taskforce member of the 6th WSPH (World Symposium on Pulmonary Hypertension)
2016 – present	Elected as Co-Chair of American Thoracic Society (ATS) Pulmonary Circulation Assembly Nominating Committee
2016 – present	Steering board member for Collaborative Research Center (CRC1213), Pulmonale Hypertonie und Cor pulmonale
2016 – current	Representative of Junior Scientist at Collaborative Research Center (CRC1213), Pulmonale Hypertonie und Cor pulmonale
2016	Call to interview for “European Research Council (ERC) Starting Grant”
2013 – 2016	Project leader: Eurostar (Joint European commission-Eureka programme)
Since 2016	Project leader of A01 and A05 at CRC 1213 (SFB 1213)
2014 – current	Programme Committee member of American Thoracic Society (ATS) Pulmonary Circulation Assembly
2012 – current	Working Group Member of the German Center for Lung Research (DZL)
2011 – current	Faculty member of University of Giessen and Marburg Lung Center
2009 – current	Faculty member of PVRI (Pulmonary Vascular Research Institute)
2010 – 2011	Awarded a Start-up Grant from the ECCPS
2009 – 2014	Project leader: International Research Training Group 1062
2007 – 2010	Project leader in Clinical Research Group Fibrosis (KFO 118/DFG)
2012 – 2018	Co-Area leader of the “Excellence Cluster for Cardio Pulmonary System”

INVITED REVIEWS

SELECTED INVITED REVIEWS		
No		Impact Factor
1.	Halawa S, Pullamsetti SS , Bangham CRM, Stenmark KR, Dorfmueller P, Frid MG, Butrous G, Morrell NW, de Jesus Perez VA, Stuart DI, O'Gallagher K, Shah AM, Aguib Y, Yacoub MH. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nat Rev Cardiol. 2021.	49.421
2.	Pullamsetti SS , Mamazhakypov A, Weissmann N, Seeger W, Savai R. Hypoxia-inducible factor signaling in pulmonary hypertension. J Clin Invest. 2020;137558.	19.477
3.	Pullamsetti SS , Schermuly R, Ghofrani A, Weissmann N, Grimminger F, Seeger W. Novel and emerging therapies for pulmonary hypertension. Am J Respir Crit Care Med. 2014 Feb 15;189(4):394-400.	30.528
4.	Pullamsetti SS , Savai R, Seeger W, Goncharova EA. Translational advances in the field of pulmonary hypertension. From cancer biology to new pulmonary arterial hypertension therapeutics. Targeting cell growth and proliferation signaling hubs. Am J Respir Crit Care Med. 2017;195:425-437.	30.528
5.	Gamen E, Seeger W, Pullamsetti SS . The emerging role of epigenetics in pulmonary hypertension. Eur Respir J. 2016 Sep;48(3):903-17.	33.801

INVITED BOOK CHAPTERS/ BOOKS

1. **Pullamsetti SS**, Schermuly RT. (2009) Chapter 5, The future treatment of pulmonary hypertension, (page 43-58), Book title: Therapeutic Strategies in Pulmonary Arterial Hypertension. Editors Peacock A.J. and Barberà J.A.
2. **Pullamsetti SS**, Schermuly RT. (2010) Chapter 16.8, Novel anti-proliferative strategies, Pulmonary Circulation, 3E, Editors Peacock AJ, Naeije R, Rubin L

RESEARCH GRANTS (CURRENT, COMPLETED)

GRANTS/ FUNDING					
No	Title	Funding Agency	Grant Acronym	Funding Period	Total amount of money (k€)
1.	Gene and cell therapy	BMBF (DZG)		2023-2025	110.000,00€
2.	Molecular analysis of COVID samples (Transcriptome and Epigenome)	BMBF	NAPKON	2021-2023	2.000.000,00€
3.	Pulmonary hypertension: "aberrant" mimicry of lung vascular morphogenesis?	ERC	Restoring Roots - 866051	2021-2025	2.000.000,00€
4.	The role of the inflammatory lung microenvironment in the transition of idiopathic pulmonary fibrosis to lung carcinoma	HMWK	LOWE-iCANx TP B1	2021-2023	252.220,00€
5.	The role of T cell subpopulations in lung cancer associated pulmonary hypertension	HMWK	LOWE-iCANx TP B4	2021-2023	126.110,00€

6.	Correction of a BMPR2 Mutation using CRISPR/Cas9-assisted Genome Editing in Familial Pulmonary Arterial Hypertension Patients	Dinosaur trust (UK)		2021-2023	300.000,00€
7.	FoxO transcription factors in PH: critical integrators of multiple signaling pathways driving vascular remodeling	DFG	SFB 1213 TP A01	2020-2024	542.800,00€
8.	Regulatory network of histone modifications in human pulmonary arterial hypertension	DFG	SFB 1213 TP A05	2020-2024	442.200,00€
9.	Nano-PAX PoC	BMBF		2019-2022	300.000,00€
10.	Research group for pulmonary hypertension	Max Planck Society (MPG)		2016-2020	960.000,00€
11.	Excellence Cluster Cardio Pulmonary system (CPI), EXC 2026	DFG		2019-2020	120.000,00€
12.	Regulatory network of histone modifications in human pulmonary arterial hypertension	DFG		2016-2020	402.400,00€
13.	FoxO transcription factors in PH: critical integrators of multiple signaling pathways driving vascular remodeling	SFB 1213 DFG		2016-2020	487.200,00€
14.	Research group for pulmonary hypertension	BMBF/DZL		2016-2020	320.000,00€
15.	FoxO- targeting strategies for the treatment of Lung Fibrosis	Von Behring-Röntgen-Stiftung (BRS)		2016-2018	300.000,00€
16.	Romain Pauwels Research Award	ERS/GSK		2016-2019	45.000,00€
17.	cAMP Enhancing approaches for treating pulmonary hypertension	Euro Star/BMBF		2014-2017	410.605,00€
18.	Epigenetic mechanisms in inflammatory and vascular alteration processes in pulmonary hypertension	BMBF		2013-2016	88.416,00€
19.	Clinical Research Group Fibrosis	KFO 118/DFG		2007-2011	427.000,00€
20.	Encysive-sponsored EtRA Young Scientist Award	Encysive		2008-2010	70.000,00€
21.	International Research Training Group 1062: Signaling mechanisms in lung physiology and disease	DFG		2009-2013	80.000,00€
22.	Start-up grant	ECCPS/DFG		2010-2011	80.000,00€
23.	Ras Association Domain Family 1A (RASSF1A)-Hippo signalling in pulmonary hypertension	Hessen state (Loewe-UGMLC)		2012 - 2014	48.000,00€

24.	Epigenetic histone modifications in pulmonary vascular remodeling – new targets for therapy in pulmonary hypertension	Hessen state (Loewe-UGMLC)		2011 - 2014	300.000,00€
25.	RASSF1A - A novel regulator of HIF signaling and metabolic phenotype of Pulmonary Hypertension	Rhön-Klinikum Förderpool		2016-2018	120.000,00€
26.	Research group for pulmonary hypertension	Max Planck Society (MPG)		2011 - 2015	1200.000,00€
27.	Impact of changes in Global Methylation Patterns and DNA methylation enzymes in diagnosis and treatment of Pulmonary Hypertension	Rhön-Klinikum Förderpool		2015-2016	90.000,00€
28.	Class II HDACs in idiopathic pulmonary fibrosis – new targets for anti-fibrotic therapy	Rhön-Klinikum Förderpool		2015-2016	90.000,00€


PATENTS

PATENTS

No

9. Gessler T, Dalla-Bona A, Schermuly RT, Seeger S, Savai R, **Pullamsetti SS**. Invention concerning nanoparticles containing taxanes for inhalation application. PCT/EP2018/073725.
10. **Pullamsetti SS**, Chelladurai P, Savai R, Seeger S. Invention concerning Benzimidazol derivatives for the treatment of pulmonary arterial hypertension. EP22167328.8 for EP1 (CSS1477) and EP22167330.4 for EP2 (SGC-CBP30).

PUBLICATION TRACK RECORD



10 SELECTED PUBLICATIONS

No		Impact Factor
1.	Chelladurai P, Kuenze C, Bourgeois A, Günther S, Valasarajan C, Cherian AV, Rottier RJ, Romanet C, Weigert A, Schmoranzner M, Boucherat O, Eichstaedt CA, Ruppert C, Guenther A, Braun T, Looso M, Savai R, Seeger W, Bauer UM, Bonnet S, Pullamsetti SS . Epigenetic reactivation of transcriptional programs orchestrating fetal lung	19.343

	development in human pulmonary hypertension. Sci Transl Med. 2022 Jun 8;14(648):eabe5407.	
2.	Kudryashova TV, Dabral S, Nayakanti S, Ray A, Goncharov DA, Avolio T, Shen Y, Rode A, Pena A, Jiang L, Lin D, Baust J, Bachman TN, Graumann J, Ruppert C, Guenther A, Schmoranzler M, Grobs Y, Eve Lemay S, Tremblay E, Breuils-Bonnet S, Boucherat O, Mora AL, DeLisser H, Zhao J, Zhao Y, Bonnet S, Seeger W, Pullamsetti SS* , Goncharova EA*. Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival. Circ Res: 130:760-778. (2022) (*equal contribution)	23.218
3.	Zehendner CM, Valasarajan C, Werner A, Boeckel JN, Bischoff FC, John D, Weirick T, Glaser SF, Rossbach O, Jaé N, Demolli S, Khassafi F, Yuan K, de Jesus Perez VA, Michalik KM, Chen W, Seeger W, Guenther A, Wasnick RM, Uchida S, Zeiher AM, Dimmeler S, Pullamsetti SS. Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-Mediated Regulation of PDGFR β . Am J Respir Crit Care Med. 202:1445-1457 (2020).	30.528
4.	Dabral S, Muecke C, Valasarajan C, Schmoranzler M, Wietelmann A, Semenza GL, Meister M, Muley T, Seeger-Nukpezah T, Samakovlis C, Weissmann N, Grimminger F, Seeger W, Savai R, Pullamsetti SS. RASSF1A-HIF1 α loop driving Warburg effect in cancer and vascular disease. Nat. Commun. 10:2130. (2019).	14.914
5.	Al-Tamari HM, Schmall A, Dabral S, Sarvari P, Paik J, DePinho RA, Grimminger F, Eickelberg O, Guenther A, Seeger W, Savai R, Pullamsetti SS. FoxO3 inactivation underlies fibrogenesis in IPF - FoxO3 reconstitution as novel treatment concept. EMBO Mol Med. 10:276-293. (2018).	12.14
6.	Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlöhner S, Rapp UR, Schermuly RT, Grimminger F, Seeger W, Savai R. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 9:eaai9048. (2017).	19.343
7.	Savai R, Al-Tamari HM, Sedding D, Kojonazarov B, Muecke C, Teske R, Capecchi MR, Weissmann N, Grimminger F, Seeger W, Schermuly RT, Pullamsetti SS. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nat Med. 20:1289-300. (2014)	87.244
8.	Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov B, Dahal BK, Ghofrani HA, Weissmann N, Grimminger F, Bonauer A, Seeger W, Zeiher AM, Dimmeler S, Schermuly RT. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med. 185:409-19. (2012).	30.528
9.	Pullamsetti SS, Savai R, Schaefer MB, Wilhelm J, Ghofrani HA, Weissmann N, Schudt C, Fleming I, Mayer K, Leiper J, Seeger W, Grimminger F, and Schermuly RT. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. Circulation. Mar 22;123(11):1194-204. (2011).	39.922
10.	Pullamsetti SS, Savai R, Dumitrascu R, Dahal BK, Wilhelm J, Königshoff M, Zakrzewicz D, Ghofrani HA, Weissmann N, Eickelberg O, Guenther A, Leiper J, Seeger W, Grimminger F, Schermuly RT. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci Transl Med. 3:87ra53. (2011).	19.343

ALL PUBLICATIONS

No		Impact Factor
----	--	---------------

1.	Nayakanti SR, Friedrich A, Sarode P, Jafari L, Maroli G, Boehm M, Bourgeois A, Grobs Y, Khassafi F, Kuenne C, Guenther S, Dabral S, Wilhelm J, Weiss A, Wietelmann A, Kojonazarov B, Janssen W, Looso M, de Man F, Provencher S, Tello K, Seeger W, Bonnet S, Savai R, Schermuly RT, Pullamsetti SS. Targeting Wnt-β-Catenin-FOSL Signaling Ameliorates Right Ventricular Remodeling. <i>Circ Res</i> . 2023 Apr 12. doi: 10.1161/CIRCRESAHA.122.321725. Epub ahead of print.	23.218
2.	Kudryashova TV, Dabral S, Nayakanti S, Ray A, Goncharov DA, Avolio T, Shen Y, Rode A, Pena A, Jiang L, Lin D, Baust J, Bachman TN, Graumann J, Ruppert C, Guenther A, Schmoranzler M, Grobs Y, Eve Lemay S, Tremblay E, Breuils-Bonnet S, Boucherat O, Mora AL, DeLisser H, Zhao J, Zhao Y, Bonnet S, Seeger W, Pullamsetti SS* , Goncharova EA*. Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival. <i>Circ Res</i> . 2022 Mar 4;130(5):760-778 (* Equal contribution).	23.218
3.	Avci E, Sarvari P, Savai R, Seeger W, Pullamsetti SS . Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets? <i>Int J Mol Sci</i> . 2022 Jan 4;23(1):546.	6.208
4.	Valasarajan C, Karger A, Savai R, Pullamsetti SS . Long Noncoding RNAs: Emerging Regulators of Platelet-derived Growth Factor Signaling. <i>Am J Respir Cell Mol Biol</i> . 2022 May;66(5):473-475.	7.748
5.	Chelladurai P, Kuenne C, Bourgeois A, Günther S, Valasarajan C, Cherian AV, Rottier RJ, Romanet C, Weigert A, Boucherat O, Eichstaedt CA, Ruppert C, Guenther A, Braun T, Looso M, Savai R, Seeger W, Bauer UM, Bonnet S, Pullamsetti SS . Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. <i>Sci Transl Med</i> . 2022 Jun 8;14(648):eabe5407.	19.343
6.	Olesch C, Brunn D, Aktay-Cetin Ö, Sirait-Fischer E, Pullamsetti SS , Grimminger F, Seeger W, Brüne B, Weigert A, Savai R. Picturing of the Lung Tumor Cellular Composition by Multispectral Flow Cytometry. <i>Front Immunol</i> . 2022 Jan 25;13:827719.	8.787
7.	Kuhnert S, Mansouri S, Rieger MA, Savai R, Avci E, Díaz-Piña G, Padmasekar M, Looso M, Hadzic S, Acker T, Klatt S, Wilhelm J, Fleming I, Sommer N, Weissmann N, Vogelmeier C, Bals R, Zeiher A, Dimmeler S, Seeger W, Pullamsetti SS . Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD. <i>Cells</i> . 2022 Jul 5;11(13):2121.	7.666
8.	Sarode P, Pullamsetti SS , Savai R. New Insights into the Epigenomic Landscape of Small Cell Lung Cancer: a Game Changer? <i>Am J Respir Crit Care Med</i> . 2022 Aug 10.	30.528
9.	Medrano-Garcia S, Morales-Cano D, Barreira B, Vera-Zambrano A, Kumar R, Kosanovic D, Schermuly RT, Graham BB, Perez-Vizcaino F, Mathie A, Savai R, Pullamsetti S , Butrous G, Fernandez-Malave E, Cogolludo A. HIV and Schistosoma Co-Exposure Leads to Exacerbated Pulmonary Endothelial Remodeling and Dysfunction Associated with Altered Cytokine Landscape. <i>Cells</i> 2022; 11.	7.666
10.	Weigert A, Zheng X, Nenzel A, Turkowski K, Günther S, Strack E, Sirait-Fischer E, Elwakeel E, Kur IM, Nikam VS, Valasarajan C, Winter H, Wissgott A, Voswinkel R, Grimminger F, Brüne B, Seeger W, Pullamsetti SS , Savai R. Fibrocytes boost tumor-supportive phenotypic switches in the lung cancer niche via the endothelin system. <i>Nat Commun</i> . 2022 Oct 14;13(1):6078.	14.919
11.	Selle J, Dinger K, Jentgen V, Zanetti D, Will J, Georgomanolis T, Vohlen C, Wilke R, Kojonazarov B, Klymenko O, Mohr J, V Koningsbruggen-Rietschel S, Rhodes CJ, Ulrich A, Hirani D, Nestler T, Odenthal M, Mahabir E, Nayakanti S, Dabral S, Wunderlich T, Priest J, Seeger W, Dötsch J, Pullamsetti SS , Alejandro Alcazar MA.	14.919

	Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life. Nat Commun. 2022 Jul 27;13(1):4352.	
12.	Rajpoot S, Solanki K, Kumar A, Zhang KYJ, Pullamsetti SS , Savai R, Faisal SM, Pan Q, Baig MS. In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern. Int J Pept Res Ther. 2022;28(1):28.	2.191
13.	Halawa S, Pullamsetti SS , Bangham CRM, Stenmark KR, Dorfmüller P, Frid MG, Butrous G, Morrell NW, de Jesus Perez VA, Stuart DI, O'Gallagher K, Shah AM, Aguib Y, Yacoub MH. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nat Rev Cardiol. 2022 May;19(5):314-331.	49.421
14.	Chelladurai P, Boucherat O, Stenmark K, Kracht M, Seeger W, Bauer UM, Bonnet S, Pullamsetti SS . Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy. Br J Pharmacol. 2021 Jan;178(1):54-71.	8.739
15.	Goncharova EA, Kudryashova TV, Maroli G, Pullamsetti SS . Matrix Metalloproteinase-8 in Pulmonary Hypertension: The Sheep in the Wolf's Skin? Am J Respir Crit Care Med. 2021 Dec 15;204(12):1361-1363.	30.528
16.	Berghausen EM, Janssen W, Vantler M, Gnatzy-Feik LL, Krause M, Behringer A, Joseph C, Zierden M, Freyhaus HT, Klinke A, Baldus S, Alcazar MA, Savai R, Pullamsetti SS , Wong DW, Boor P, Zhao JJ, Schermuly RT, Rosenkranz S. Disrupted PI3K subunit p110 α signaling protects against pulmonary hypertension and reverses established disease in rodents. J Clin Invest. 2021 Oct 1;131(19):e136939.	19.477
17.	Eul B, Cekay M, Tello K, Wilhelm J, Gattenlöhner S, Sibelius U, Grimminger F, Seeger W, Pullamsetti SS , Savai R. Reply to Zheng <i>et al.</i> Am J Respir Crit Care Med. 2021 Nov 1;204(9):1113.	30.528
18.	Padmasekar M, Savai R, Seeger W, Pullamsetti SS . Exosomes to Exosomes: Exosomes as Tools to Study Epigenetic Adaptive Mechanisms in High-Altitude Humans. Int J Environ Res Public Health. 2021 Aug 5;18(16):8280.	4.614
19.	Karger A, Nandigama R, Stenzinger A, Grimminger F, Pullamsetti SS , Seeger W, Savai R. Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. Cancers (Basel). 2021 Aug 17;13(16):4127.	6.639
20.	Qi H, Liu H, Pullamsetti SS , Günther S, Kuenne C, Atzberger A, Sommer N, Hadzic S, Günther A, Weissmann N, Zhou Y, Yuan X, Braun T. Epigenetic Regulation by <i>Suv4-20h1</i> in Cardiopulmonary Progenitor Cells Is Required to Prevent Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Circulation. 2021 Sep 28;144(13):1042-1058.	39.922
21.	Ianni A, Hofmann M, Kumari P, Tarighi S, Al-Tamari HM, Görgens A, Giebel B, Nolte H, Krüger M, Salwig I, Pullamsetti SS , Günther A, Schneider A, Braun T. Depletion of <i>Numb</i> and <i>Numbl</i> in Murine Lung Epithelial Cells Ameliorates Bleomycin-Induced Lung Fibrosis by Inhibiting the β -Catenin Signaling Pathway. Front Cell Dev Biol. 2021 May 26;9:639162.	6.081
22.	Pullamsetti SS , Tello K, Seeger W. Utilising biomarkers to predict right heart maladaptive phenotype: a step toward precision medicine. Eur Respir J. 2021 Apr 8;57(4):2004506.	33.801
23.	Brunn D, Turkowski K, Günther S, Weigert A, Muley T, Kriegsmann M, Winter H, Dammann RH, Stathopoulos GT, Thomas M, Guenther A, Grimminger F, Pullamsetti SS , Seeger W, Savai R. Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. Cancers (Basel). 2021 Jan 8;13(2):208.	6.639
24.	Eul B, Cekay M, Pullamsetti SS , Tello K, Wilhelm J, Gattenlöhner S, Sibelius U, Grimminger F, Seeger W, Savai R. Noninvasive Surrogate Markers of Pulmonary	30.528

	Hypertension Are Associated with Poor Survival in Patients with Lung Cancer. Am J Respir Crit Care Med. 2021 May 15;203(10):1316-1319.	
25.	Keranov S, Dörr O, Jafari L, Troidl C, Liebetau C, Kriechbaum S, Keller T, Voss S, Bauer T, Lorenz J, Richter MJ, Tello K, Gall H, Ghofrani HA, Mayer E, Wiedenroth CB, Guth S, Lörchner H, Pöling J, Chelladurai P, Pullamsetti SS , Braun T, Seeger W, Hamm CW, Nef H. CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. Eur Respir J. 2021 Apr 1;57(4):1901192.	33.801
26.	Chelladurai P, Savai R, Pullamsetti SS . Zooming into Cellular and Molecular Heterogeneity of Pulmonary Hypertension. What More Single-Cell Omics Can Offer. Am J Respir Crit Care Med. 2021 Apr 15;203(8):941-943.	30.528
27.	Zheng X, Weigert A, Reu S, Guenther S, Mansouri S, Bassaly B, Gattenlöhner S, Grimminger F, Pullamsetti S , Seeger W, Winter H, Savai R. Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma. Cancer Res. 2020 Oct 15;80(20):4414-4425.	13.312
28.	El-Nikhely N, Karger A, Sarode P, Singh I, Weigert A, Wietelmann A, Stiewe T, Dammann R, Fink L, Grimminger F, Barreto G, Seeger W, Pullamsetti SS , Rapp UR, Savai R. Metastasis-Associated Protein 2 Represses NF-κB to Reduce Lung Tumor Growth and Inflammation. Cancer Res. 2020 Oct 1;80(19):4199-4211. IF: 13.31	13.312
29.	Zheng X, Mansouri S, Krager A, Grimminger F, Seeger W, Pullamsetti SS , Wheelock CE, Savai R. Metabolism in tumour-associated macrophages: a <i>quid pro quo</i> with the tumour microenvironment. Eur Respir Rev. 2020 Oct 1;29(157):200134.	9.553
30.	Pullamsetti SS , Nayakanti S, Chelladurai P, Mamazhakypov A, Mansouri S, Savai R, Seeger W. Cancer and pulmonary hypertension: Learning lessons and real-life interplay. Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202010.	
31.	Pullamsetti SS , Mamazhakypov A, Weissmann N, Seeger W, Savai R. Hypoxia-inducible factor signaling in pulmonary hypertension. J Clin Invest. 2020 Nov 2;130(11):5638-5651.	19.477
32.	Salazar Y, Zheng X, Brunn D, Raifer H, Picard F, Zhang Y, Winter H, Guenther S, Weigert A, Weigmann B, Dumoutier L, Renauld JC, Waisman A, Schmall A, Tufman A, Fink L, Brüne B, Bopp T, Grimminger F, Seeger W, Pullamsetti SS , Huber M, Savai R. Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. J Clin Invest. 2020 Jul 1;130(7):3560-3575.	19.477
33.	Rakow S, Pullamsetti SS , Bauer UM, Bouchard C. Assaying epigenome functions of PRMTs and their substrates. Methods. 2020 Mar 15;175:53-65.	4.647
34.	Sindi HA, Russomanno G, Satta S, Abdul-Salam VB, Jo KB, Qazi-Chaudhry B, Ainscough AJ, Szulcek R, Jan Bogaard H, Morgan CC, Pullamsetti SS , Alzaydi MM, Rhodes CJ, Piva R, Eichstaedt CA, Grünig E, Wilkins MR, Wojciak-Stothard B. Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nat Commun. 2020 Mar 4;11(1):1185.	17.694
35.	Chelladurai P, Dabral S, Basineni SR, Chen CN, Schmoranz M, Bender N, Feld C, Nötzold RR, Dobрева G, Wilhelm J, Jungblut B, Zhao L, Bauer UM, Seeger W, Pullamsetti SS . Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension. Sci Rep. 2020 Jul 30;10(1):12864.	4.997
36.	Pullamsetti SS , Günther A. A FOX-like Mechanism Regulating Lung Fibroblasts: Are We Getting There? Am J Respir Cell Mol Biol. 2020 Dec;63(6):723-724.	7.748
37.	Zehendner CM, Valasarajan C, Werner A, Boeckel JN, Bischoff FC, John D, Weirick T, Glaser SF, Rossbach O, Jaé N, Demolli S, Khassafi F, Yuan K, de Jesus Perez VA, Michalik KM, Chen W, Seeger W, Guenther A, Wasnick RM, Uchida S, Zeiher AM, Dimmeler S, Pullamsetti SS . Long Noncoding RNA TYKRIL Plays a Role in	30.528

	Pulmonary Hypertension via the p53-mediated Regulation of PDGFR β . Am J Respir Crit Care Med. 2020 Nov 15;202(10):1445-1457.	
38.	Sarode P, Zheng X, Giotopoulou GA, Weigert A, Kuenne C, Günther S, Friedrich A, Gattenlöhner S, Stiewe T, Brüne B, Grimminger F, Stathopoulos GT, Pullamsetti SS , Seeger W, Savai R. Reprogramming of tumor-associated macrophages by targeting β -catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. Sci Adv. 2020 Jun 5;6(23):eaaz6105.	14.980
39.	Küster MM, Schneider MA, Richter AM, Richtmann S, Winter H, Kriegsmann M, Pullamsetti SS , Stiewe T, Savai R, Muley T, Dammann RH. Epigenetic Inactivation of the Tumor Suppressor <i>IRX1</i> Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. Cancers (Basel). 2020 Nov 26;12(12):3528.	6.639
40.	Mamazhakypov A, Weiß A, Zukunft S, Sydykov A, Kojonazarov B, Wilhelm J, Vroom C, Petrovic A, Kosanovic D, Weissmann N, Seeger W, Fleming I, Iglarz M, Grimminger F, Ghofrani HA, Pullamsetti SS , Schermuly RT. Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. Pulm Circ. 2020 Nov 11;10(4):2045894020947283.	2.886
41.	Chelladurai P, Dabral S, Basineni SR, Chen CN, Schmoranzler M, Bender N, Feld C, Nötzold RR, Dobrev G, Wilhelm J, Jungblut B, Zhao L, Bauer UM, Seeger W, Pullamsetti SS . Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension. Sci Rep. 2020 Jul 30;10(1):12864.	4.997
42.	Turkowski K, Herzberg F, Günther S, Brunn D, Weigert A, Meister M, Muley T, Kriegsmann M, Schneider MA, Winter H, Thomas M, Grimminger F, Seeger W, Savai Pullamsetti S , Savai R. Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas. Cells. 2020 Jul 22;9(8):1755.	7.666
43.	Bensimon-Brito A, Ramkumar S, Boezio GLM, Guenther S, Kuenne C, Helker CSM, Sánchez-Iranzo H, Iloska D, Piesker J, Pullamsetti S , Mercader N, Beis D, Stainier DYR. TGF- β Signaling Promotes Tissue Formation during Cardiac Valve Regeneration in Adult Zebrafish. Dev Cell. 2020 Jan 6;52(1):9-20.e7.	13.417
44.	Bensimon-Brito A, Ramkumar S, Boezio GLM, Guenther S, Kuenne C, Helker CSM, Sánchez-Iranzo H, Iloska D, Piesker J, Pullamsetti S , Mercader N, Beis D, Stainier DYR. TGF- β Signaling Promotes Tissue Formation during Cardiac Valve Regeneration in Adult Zebrafish. Dev Cell. 2020 Jan 6;52(1):9-20.e7.	13.42
45.	Spiekerkoetter E, Goncharova EA, Guignabert C, Stenmark K, Kwapiszewska G, Rabinovitch M, Voelkel N, Bogaard HJ, Graham B, Pullamsetti SS , Kuebler WM. Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure. Pulm Circ. 2019 Nov 20;9(4):2045894019889775.	2.886
46.	Weiss A, Boehm M, Egemnazarov B, Grimminger F, Savai Pullamsetti S , Kwapiszewska G, Schermuly RT. Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. Br J Pharmacol. 2019 Nov 10.	8.31
47.	Rubio K, Singh I, Dobersch S, Sarvari P, Günther S, Cordero J, Mehta A, Wujak L, Cabrera-Fuentes H, Chao CM, Braubach P, Bellusci S, Seeger W, Günther A, Preissner KT, Wygrecka M, Savai R, Papy-Garcia D, Dobrev G, Heikenwalder M, Savai-Pullamsetti S , Braun T, Barreto G. Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis. Nat Commun. 2019 May 20;10(1):2229.	14.919
48.	Rakow S, Pullamsetti SS , Bauer UM, Bouchard C. Assaying epigenome functions of PRMTs and their substrates. Methods. 2020 Mar 15;175:53-65.	4.647

49.	Pullamsetti SS , de Jesus Perez VA. EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition. Am J Respir Crit Care Med. 2019 Nov 1;200(9):1188-1190.	30.528
50.	Weiss A, Neubauer MC, Yerabolu D, Kojonazarov B, Schlueter BC, Neubert L, Jonigk D, Baal N, Ruppert C, Dorfmüller P, Pullamsetti SS , Weissmann N, Ghofrani HA, Grimminger F, Seeger W, Schermuly RT. Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nat Commun. 2019 May 17;10(1):2204.	14.919
51.	Dabral S, Muecke C, Valasarajan C, Schmoranzner M, Wietelmann A, Semenza GL, Meister M, Muley T, Seeger-Nukpezah T, Samakovlis C, Weissmann N, Grimminger F, Seeger W, Savai R, Pullamsetti SS . A RASSF1A-HIF1 α loop drives Warburg effect in cancer and pulmonary hypertension. Nat Commun. 2019 May 13;10(1):2130.	14.919
52.	Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS , Schermuly RT, Stenmark KR, Rabinovitch M. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan 24;53(1):1801887.	33.801
53.	Korfei M, Stelmaszek D, MacKenzie B, Skwarna S, Chillappagari S, Bach AC, Ruppert C, Saito S, Mahavadi P, Klepetko W, Fink L, Seeger W, Lasky JA, Pullamsetti SS , Krämer OH, Guenther A. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS One. 2018 Nov 27;13(11):e0207915.	3.752
54.	Bouchard C, Sahu P, Meixner M, Nötzold RR, Rust MB, Kremmer E, Feederle R, Hart-Smith G, Finkernagel F, Bartkuhn M, Savai Pullamsetti S , Nist A, Stiewe T, Philipsen S, Bauer UM. Genomic Location of PRMT6-Dependent H3R2 Methylation Is Linked to the Transcriptional Outcome of Associated Genes. Cell Rep. 2018 Sep 18;24(12):3339-3352.	9.995
55.	Ashek A, Spruijt OA, Harms HJ, Lammertsma AA, Cupitt J, Dubois O, Wharton J, Dabral S, Pullamsetti SS , Huisman MC, Frings V, Boellaard R, de Man FS, Botros L, Jansen S, Vonk Noordegraaf A, Wilkins MR, Bogaard HJ, Zhao L. 3 ¹ -Deoxy-3 ¹ -[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. Circ Cardiovasc Imaging. 2018 Aug;11(8):e007402.	7.792
56.	Olschewski A, Berghausen EM, Eichstaedt CA, Fleischmann BK, Grünig E, Grünig G, Hansmann G, Harbaum L, Hennigs JK, Jonigk D, Kuebler WM, Kwapiszewska G, Pullamsetti SS , Stacher E, Weissmann N, Wenzel D, Schermuly RT. Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:4-10.	4.039
57.	Sommer N, Droege F, Gamen KE, Geisthoff U, Gall H, Tello K, Richter MJ, Deubner LM, Schmiedel R, Hecker M, Spiekerkoetter E, Wirsching K, Seeger W, Ghofrani HA, Pullamsetti S . Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. Pulm Circ. 2019 Apr-Jun;9(2):2045894018805406.	2.886
58.	Hu CJ, Zhang H, Laux A, Pullamsetti SS , Stenmark KR. Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension. J Physiol. 2019 Feb;597(4):1103-1119.	6.228
59.	Stenmark KR, Hu CJ, Pullamsetti SS . How Many FOXs Are There on The Road to Pulmonary Hypertension? Am J Respir Crit Care Med. 2018 Sep 15;198(6):704-707.	30.528

60.	Pullamsetti SS , Seeger W, Savai R. Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension. J Clin Invest. 2018 May 1;128(5):1720-1723.	19.477
61.	Josipovic I, Pflüger B, Fork C, Vasconez AE, Oo JA, Hitzel J, Seredinski S, Gamen E, Heringdorf DMZ, Chen W, Looso M, Pullamsetti SS , Brandes RP, Leisegang MS. Long noncoding RNA LISPR1 is required for S1P signaling and endothelial cell function. J Mol Cell Cardiol. 2018 Mar;116:57-68.	5.763
62.	Al-Tamari HM, Dabral S, Schmall A, Sarvari P, Ruppert C, Paik J, DePinho RA, Grimminger F, Eickelberg O, Guenther A, Seeger W, Savai R, Pullamsetti SS . FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Mol Med. 2018 Feb;10(2):276-293.	14.260
63.	Pullamsetti SS , Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlöhner S, Rapp UR, Schermuly RT, Grimminger F, Seeger W, Savai R. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017 Nov 15;9(416):eaai9048.	19.36
64.	Hautefort A, Chesné J, Preussner J, Pullamsetti SS , Tost J, Looso M, Antigny F, Girerd B, Riou M, Eddahibi S, Deleuze JF, Seeger W, Fadel E, Simonneau G, Montani D, Humbert M, Perros F. Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. Oncotarget. 2017 May 19;8(32):52995-53016.	5.168
65.	Dabral S, Pullamsetti SS . Vascular Stiffness and Mechanotransduction: Back in the Limelight. Am J Respir Crit Care Med. 2017 Aug 15;196(4):527-530.	30.528
66.	Vohwinkel CU, Buchäckert Y, Al-Tamari HM, Mazzocchi LC, Eltzhig HK, Mayer K, Morty RE, Herold S, Seeger W, Pullamsetti SS , Vadász I. Restoration of Megalin-Mediated Clearance of Alveolar Protein as a Novel Therapeutic Approach for Acute Lung Injury. Am J Respir Cell Mol Biol. 2017 Nov;57(5):589-602.	7.748
67.	Kiehl S, Zimmermann T, Savai R, Pullamsetti SS , Seeger W, Bartkuhn M, Dammann RH. Epigenetic silencing of downstream genes mediated by tandem orientation in lung cancer. Sci Rep. 2017 Jun 20;7(1):3896.	4.996
68.	Bischoff FC, Werner A, John D, Boeckel JN, Melissari MT, Grote P, Glaser SF, Demolli S, Uchida S, Michalik KM, Meder B, Katus HA, Haas J, Chen W, Pullamsetti SS , Seeger W, Zeiher AM, Dimmeler S, Zehendner CM. Identification and Functional Characterization of Hypoxia-Induced Endoplasmic Reticulum Stress Regulating lncRNA (HypERlnc) in Pericytes. Circ Res. 2017 Aug 4;121(4):368-375.	23.218
69.	Pullamsetti SS , Savai R. Macrophage Regulation during Vascular Remodeling: Implications for Pulmonary Hypertension Therapy. Am J Respir Cell Mol Biol. 2017 May;56(5):556-558.	7.748
70.	Leisegang MS, Fork C, Josipovic I, Richter FM, Preussner J, Hu J, Miller MJ, Epah J, Hofmann P, Günther S, Moll F, Valasarajan C, Heidler J, Ponomareva Y, Freiman TM, Maegdefessel L, Plate KH, Mittelbronn M, Uchida S, Küne C, Stellos K, Schermuly RT, Weissmann N, Devraj K, Wittig I, Boon RA, Dimmeler S, Pullamsetti SS , Looso M, Miller FJ Jr, Brandes RP. Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function. Circulation. 2017 Jul 4;136(1):65-79.	39.922
71.	Dabral S, Tian X, Kojonazarov B, Savai R, Ghofrani HA, Weissmann N, Florio M, Sun J, Jonigk D, Maegel L, Grimminger F, Seeger W, Pullamsetti S , Schermuly RT. Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. Eur Respir J. 2016 Oct;48(4):1137-1149.	33.801
72.	Pullamsetti SS , Perros F, Chelladurai P, Yuan J, Stenmark K. Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of	2.886

	pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series). Pulm Circ. 2016 Dec;6(4):448-464.	
73.	Olschewski A, Berghausen EM, Eichstaedt CA, Fleischmann BK, Grünig E, Grünig G, Hansmann G, Harbaum L, Hennigs JK, Jonigk D, Kübler WM, Kwapiszewska G, Pullamsetti SS , Stacher E, Weissmann N, Wenzel D, Schermuly RT. Pathobiologie, Pathologie und Genetik der pulmonalen Hypertonie: Empfehlungen der Kölner Konsensus-Konferenz 2016 [Pathobiology, pathology and genetics of pulmonary hypertension: Recommendations of the Cologne Consensus Conference 2016]. Dtsch Med Wochenschr. 2016 Oct;141(S 01):S4-S9. German.	0.628
74.	Li M, Riddle S, Zhang H, D'Alessandro A, Flockton A, Serkova NJ, Hansen KC, Moldovan R, McKeon BA, Frid M, Kumar S, Li H, Liu H, Caánovas A, Medrano JF, Thomas MG, Iloska D, Plecítá-Hlavatá L, Ježek P, Pullamsetti S , Fini MA, El Kasmi KC, Zhang Q, Stenmark KR. Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1. Circulation. 2016 Oct 11;134(15):1105-1121.	39.922
75.	Pullamsetti SS , Savai R, Seeger W, Goncharova EA. Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. Am J Respir Crit Care Med. 2017 Feb 15;195(4):425-437.	30.528
76.	Gamen E, Seeger W, Pullamsetti SS . The emerging role of epigenetics in pulmonary hypertension. Eur Respir J. 2016 Sep;48(3):903-17.	33.801
77.	Chelladurai P, Seeger W, Pullamsetti SS . Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives. Eur Respir Rev. 2016 Jun;25(140):135-40.	9.553
78.	Josipovic I, Fork C, Preussner J, Prior KK, Iloska D, Vasconez AE, Labocha S, Angioni C, Thomas D, Ferreirós N, Looso M, Pullamsetti SS , Geisslinger G, Steinhilber D, Brandes RP, Leisegang MS. PFAH1B1 and the lncRNA NONHSAT073641 maintain an angiogenic phenotype in human endothelial cells. Acta Physiol (Oxf). 2016 Sep;218(1):13-27.	6.311
79.	Shi L, Kojonazarov B, Elgheznawy A, Popp R, Dahal BK, Böhm M, Pullamsetti SS , Ghofrani HA, Gödecke A, Jungmann A, Katus HA, Müller OJ, Schermuly RT, Fisslthaler B, Seeger W, Fleming I. miR-223-IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. Cardiovasc Res. 2016 Aug 1;111(3):184-93.	13.081
80.	Plecítá-Hlavatá L, Tauber J, Li M, Zhang H, Flockton AR, Pullamsetti SS , Chelladurai P, D'Alessandro A, El Kasmi KC, Ježek P, Stenmark KR. Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2016 Jul;55(1):47-57.	7.748
81.	Banat GA, Tretyn A, Pullamsetti SS , Wilhelm J, Weigert A, Olesch C, Ebel K, Stiewe T, Grimminger F, Seeger W, Fink L, Savai R. Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. PLoS One. 2015 Sep 28;10(9):e0139073.	3.752
82.	Korfei M, Skwarna S, Henneke I, MacKenzie B, Klymenko O, Saito S, Ruppert C, von der Beck D, Mahavadi P, Klepetko W, Bellusci S, Crestani B, Pullamsetti SS , Fink L, Seeger W, Krämer OH, Guenther A. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax. 2015 Nov;70(11):1022-32.	9.102
83.	Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, Luitel H, Murmann K, Krompiec DR, Tretyn A, Pullamsetti SS , Weissmann N,	3.411

	Seeger W, Ghofrani HA, Schermuly RT. 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. Biomed Res Int. 2015;2015:438403.	
84.	Schmall A, Al-Tamari HM, Herold S, Kampschulte M, Weigert A, Wietelmann A, Vipotnik N, Grimminger F, Seeger W, Pullamsetti SS , Savai R. Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. Am J Respir Crit Care Med. 2015 Feb 15;191(4):437-47.	30.528
85.	Riemekasten G, Kuebler WM, Schermuly R, Seyfarth HJ, Behr J, Grohe C, Hoepfer MM, Olschewski A, Kwapiszewska G, Ulrich S, Voswinckel R, Weissmann N, Worth H, Viales RR, Pullamsetti SS , Grunig G. Die pulmonal arterielle Hypertonie—auch eine Erkrankung des Immunsystems? [Pulmonary arterial hypertension—a disease of the immune system?]. Dtsch Med Wochenschr. 2014 Dec;139 Suppl 4:S116-20.	0.628
86.	Savai R, Al-Tamari HM, Sedding D, Kojonazarov B, Muecke C, Teske R, Capecchi MR, Weissmann N, Grimminger F, Seeger W, Schermuly RT, Pullamsetti SS . Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nat Med. 2014 Nov;20(11):1289-300.	87.241
87.	El Kasmi KC, Pugliese SC, Riddle SR, Poth JM, Anderson AL, Frid MG, Li M, Pullamsetti SS , Savai R, Nagel MA, Fini MA, Graham BB, Tuder RM, Friedman JE, Eltzschig HK, Sokol RJ, Stenmark KR. Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. J Immunol. 2014 Jul 15;193(2):597-609.	5.446
88.	Pullamsetti SS , Schermuly R, Ghofrani A, Weissmann N, Grimminger F, Seeger W. Novel and emerging therapies for pulmonary hypertension. Am J Respir Crit Care Med. 2014 Feb 15;189(4):394-400.	30.528
89.	Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS , Velegala S, Seeger W, McKinsey TA, Sucharov CC, Stenmark KR. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res. 2014 Jan 3;114(1):67-78.	23.218
90.	Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS , Cotroneo E, Jones H, Tomasi G, Nguyen QD, Aboagye EO, El-Bahrawy MA, Barnes G, Howard LS, Gibbs JS, Gsell W, He JG, Wilkins MR. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation. 2013 Sep 10;128(11):1214-24.	39.922
91.	Seeger W, Pullamsetti SS . Mechanics and mechanisms of pulmonary hypertension-Conference summary and translational perspectives. Pulm Circ. 2013 Jan;3(1):128-36.	2.886
92.	Sedding DG, Widmer-Teske R, Mueller A, Stieger P, Daniel JM, Gündüz D, Pullamsetti S , Nef H, Moellmann H, Troidl C, Hamm C, Braun-Dullaeus R. Role of the phosphatase PTEN in early vascular remodeling. PLoS One. 2013;8(3):e55445.	3.752
93.	Janssen W, Pullamsetti SS , Cooke J, Weissmann N, Guenther A, Schermuly RT. The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. J Pathol. 2013 Jan;229(2):242-9.	9.883
94.	Savai R, Pullamsetti SS , Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klusmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Nov 1;186(9):897-908.	30.528

95.	Kojonazarov B, Sydykov A, Pullamsetti SS , Luitel H, Dahal BK, Kosanovic D, Tian X, Majewski M, Baumann C, Evans S, Phillips P, Fairman D, Davie N, Wayman C, Kilty I, Weissmann N, Grimminger F, Seeger W, Ghofrani HA, Schermuly RT. Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. <i>Int J Cardiol.</i> 2013 Sep 10;167(6):2630-7.	4.039
96.	Mihaylova S, Killian A, Mayer K, Pullamsetti SS , Schermuly R, Rosengarten B. Effects of anti-inflammatory vagus nerve stimulation on the cerebral microcirculation in endotoxemic rats. <i>J Neuro inflammation.</i> 2012 Jul 25;9:183.	9.587
97.	Pullamsetti SS , Banat GA, Schmall A, Szibor M, Pomagruk D, Hänze J, Kolosionek E, Wilhelm J, Braun T, Grimminger F, Seeger W, Schermuly RT, Savai R. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. <i>Oncogene.</i> 2013 Feb 28;32(9):1121-34.	8.756
98.	Chelladurai P, Seeger W, Pullamsetti SS . Matrix metalloproteinases and their inhibitors in pulmonary hypertension. <i>Eur Respir J.</i> 2012 Sep;40(3):766-82.	33.801
99.	Pullamsetti SS , Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Rosenkranz S, Schermuly RT. Role of Src tyrosine kinases in experimental pulmonary hypertension. <i>Arterioscler Thromb Vasc Biol.</i> 2012 Jun;32(6):1354-65.	10.514
100.	Pullamsetti SS , Doebele C, Fischer A, Savai R, Kojonazarov B, Dahal BK, Ghofrani HA, Weissmann N, Grimminger F, Bonauer A, Seeger W, Zeiher AM, Dimmeler S, Schermuly RT. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. <i>Am J Respir Crit Care Med.</i> 2012 Feb 15;185(4):409-19.	30.528
101.	Dahal BK, Heuchel R, Pullamsetti SS , Wilhelm J, Ghofrani HA, Weissmann N, Seeger W, Grimminger F, Schermuly RT. Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor- β . <i>Pulm Circ.</i> 2011 Apr-Jun;1(2):259-68.	2.886
102.	Pullamsetti SS , Savai R, Dumitrascu R, Dahal BK, Wilhelm J, Konigshoff M, Zakrzewicz D, Ghofrani HA, Weissmann N, Eickelberg O, Guenther A, Leiper J, Seeger W, Grimminger F, Schermuly RT. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. <i>Sci Transl Med.</i> 2011 Jun 15;3(87):87ra53.	19.359
103.	Sklepkiwicz P, Schermuly RT, Tian X, Ghofrani HA, Weissmann N, Sedding D, Kashour T, Seeger W, Grimminger F, Pullamsetti SS . Glycogen synthase kinase 3 β contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. <i>PLoS One.</i> 2011 Apr 18;6(4):e18883.	3.752
104.	Tian X, Vroom C, Ghofrani HA, Weissmann N, Bieniek E, Grimminger F, Seeger W, Schermuly RT, Pullamsetti SS . Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. <i>PLoS One.</i> 2011 Apr 11;6(4):e18136.	3.752
105.	Pullamsetti SS , Savai R, Schaefer MB, Wilhelm J, Ghofrani HA, Weissmann N, Schudt C, Fleming I, Mayer K, Leiper J, Seeger W, Grimminger F, Schermuly RT. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. <i>Circulation.</i> 2011 Mar 22;123(11):1194-204.	39.922
106.	Nguewa PA, Calvo A, Pullamsetti SS , Banat GA, Grimminger F, Savai R. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. <i>Expert Opin Investig Drugs.</i> 2011 Jan;20(1):61-74.	6.498
107.	Nikolova S, Guenther A, Savai R, Weissmann N, Ghofrani HA, Konigshoff M, Eickelberg O, Klepetko W, Voswinckel R, Seeger W, Grimminger F, Schermuly RT,	7.162

	Pullamsetti SS. Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. Respir Res. 2010 Oct 27;11(1):146.	
108.	Dumitrascu R, Kulcke C, Königshoff M, Kouri F, Yang X, Morrell N, Ghofrani HA, Weissmann N, Reiter R, Seeger W, Grimminger F, Eickelberg O, Schermuly RT, Pullamsetti SS. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J. 2011 May;37(5):1104-18.	33.801
109.	Pullamsetti SS, Savai R, Janssen W, Dahal BK, Seeger W, Grimminger F, Ghofrani HA, Weissmann N, Schermuly RT. Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clin Microbiol Infect. 2011 Jan;17(1):7-14.	13.310
110.	Udalov S, Dumitrascu R, Pullamsetti SS, Al-tamari HM, Weissmann N, Ghofrani HA, Guenther A, Voswinckel R, Seeger W, Grimminger F, Schermuly RT. Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm Med. 2010 May 5;10:26.	3.320
111.	Savai R, Pullamsetti SS, Banat GA, Weissmann N, Ghofrani HA, Grimminger F, Schermuly RT. Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs. 2010 Jan;19(1):117-31.	6.498
112.	Dahal BK, Cornitescu T, Tretyn A, Pullamsetti SS, Kosanovic D, Dumitrascu R, Ghofrani HA, Weissmann N, Voswinckel R, Banat GA, Seeger W, Grimminger F, Schermuly RT. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med. 2010 Jan 15;181(2):158-67.	30.528
113.	Kolosionek E, Savai R, Ghofrani HA, Weissmann N, Guenther A, Grimminger F, Seeger W, Banat GA, Schermuly RT, Pullamsetti SS. Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. Mol Biol Cell. 2009 Nov;20(22):4751-65.	3.612
114.	Weissmann N, Hackemack S, Dahal BK, Pullamsetti SS, Savai R, Mittal M, Fuchs B, Medebach T, Dumitrascu R, Eickels Mv, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT. The soluble guanylate cyclase activator HMR1766 reverses hypoxia- induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2009 Oct;297(4):L658-65.	6.011
115.	Pullamsetti SS, Schermuly RT. Endothelin receptor antagonists in preclinical models of pulmonary hypertension. Eur J Clin Invest. 2009 Jun;39 Suppl 2:3-13.	19.477
116.	Savai R, Langheinrich AC, Schermuly RT, Pullamsetti SS, Dumitrascu R, Traupe H, Rau WS, Seeger W, Grimminger F, Banat GA. Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia. 2009 Jan;11(1):48-56.	6.218
117.	Dumitrascu R, Koebrich S, Dony E, Weissmann N, Savai R, Pullamsetti SS, Ghofrani HA, Samidurai A, Traupe H, Seeger W, Grimminger F, Schermuly RT. Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulm Med. 2008 Dec 17;8:25.	3.320
118.	Woyda K, Koebrich S, Reiss I, Rudloff S, Pullamsetti SS, Rühlmann A, Weissmann N, Ghofrani HA, Günther A, Seeger W, Grimminger F, Morty RE, Schermuly RT. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J. 2009 Apr;33(4):861-70.	33.801
119.	Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schäfer S. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation. 2008 Nov 11;118(20):2081-90.	39.922
120.	Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Müller D, Schlüter KD, Dingendorf A, Hackemack S, Kolosionek E, Kaulen C, Dumitrascu R, Weissmann	33.801

	N, Mittendorf J, Klepetko W, Seeger W, Ghofrani HA, Grimminger F. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008 Oct;32(4):881-91.	
121.	Lai YJ, Pullamsetti SS , Dony E, Weissmann N, Butrous G, Banat GA, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am J Respir Crit Care Med. 2008 Jul 15;178(2):188-96.	30.528
122.	Dony E, Lai YJ, Dumitrascu R, Pullamsetti SS , Savai R, Ghofrani HA, Weissmann N, Schudt C, Flockerzi D, Seeger W, Grimminger F, Schermuly RT. Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. Eur Respir J. 2008 Mar;31(3):599-610.	33.801
123.	Savai R, Schermuly RT, Pullamsetti SS , Schneider M, Greschus S, Ghofrani HA, Traupe H, Grimminger F, Banat GA. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Cancer Res. 2007 Jun 1;67(11):5443-53.	13.312
124.	Patel HH, Zhang S, Murray F, Suda RY, Head BP, Yokoyama U, Swaney JS, Niesman IR, Schermuly RT, Pullamsetti SS , Thistlethwaite PA, Miyanojara A, Farquhar MG, Yuan JX, Insel PA. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB J. 2007 Sep;21(11):2970-9.	5.834
125.	Schermuly RT*, Pullamsetti SS* , Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, Ghofrani HA, Kaulen C, Dunkern T, Schudt C, Voswinckel R, Zhou J, Samidurai A, Klepetko W, Paddenberg R, Kummer W, Seeger W, Grimminger F. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation. 2007 May 1;115(17):2331-9. (*Equal contribution)	39.922
126.	Schermuly RT, Pullamsetti SS , Breitenbach SC, Weissmann N, Ghofrani HA, Grimminger F, Nilius SM, Schrör K, Kirchrath JM, Seeger W, Rose F. Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res. 2007 Jan 26;8(1):4.	7.162
127.	Pullamsetti SS , Maring D, Ghofrani HA, Mayer K, Weissmann N, Rosengarten B, Lehner M, Schudt C, Boer R, Grimminger F, Seeger W, Schermuly RT. Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. Thromb Haemost. 2006 Apr;95(4):720-7.	5.249
128.	Savai R, Schermuly RT, Schneider M, Pullamsetti SS , Grimminger F, Seeger W, Banat GA. Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice. J Immunother. 2006 Mar-Apr;29(2):175-87.	4.912
129.	Pullamsetti S , Krick S, Yilmaz H, Ghofrani HA, Schudt C, Weissmann N, Fuchs B, Seeger W, Grimminger F, Schermuly RT. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res. 2005 Nov 1;6(1):128.	7.162
130.	Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S , Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005 Oct;115(10):2811-21.	19.477
131.	Grandel U, Hopf M, Buerke M, Hattar K, Heep M, Fink L, Bohle RM, Morath S, Hartung T, Pullamsetti S , Schermuly RT, Seeger W, Grimminger F, Sibelius U. Mechanisms of cardiac depression caused by lipoteichoic acids from Staphylococcus aureus in isolated rat hearts. Circulation. 2005 Aug 2;112(5):691-8	39.922

132.	Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S , Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med. 2005 Aug 1;172(3):358-63.	30.528
133.	Pullamsetti S , Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W, Aigner C, Fink L, Muyal JP, Weissmann N, Grimminger F, Seeger W, Schermuly RT. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J. 2005 Jul;19(9):1175-7.	5.834
134.	Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S , Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res. 2004 Apr 30;94(8):1101-8.	23.218

ABSTRACT PRESENTATIONS

More than 20 abstracts will be submitted each year from my group to National and International Scientific Meetings such as DGP, ERS, ESC, ATS, AHA, PVRI and others..

CLINICAL ACTIVITIES

Though I am not a clinician, I am involved and driving various biomarker projects (Transcriptomics, epigenomics and proteomics) from clinical samples of pulmonary hypertension patients. As well, I am leading the national epigenomic studies of COVID samples collected by German National Pandemic Cohort Network (NAPKON).